Business Context and Reporting Period
Company: Coherus BioSciences, Inc. (CHRS)
Filing Type: Form 8-K (Current Report)
Date of Report: December 26, 2023
Event: FDA Approval of UDENYCA ONBODY®
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a regulatory event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change reported is the U.S. Food and Drug Administration (FDA) approval of UDENYCA ONBODY®, an on-body injector (OBI) presentation of the Company's pegfilgrastim biosimilar, UDENYCA® (pegfilgrastim-cbqv).
- Product Function: Administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.
- Key Features: Includes an indicator/status light, auditive signal for dose confirmation, strong adhesive, and automatic needle retraction to reduce needlestick injury risk.
- Approval Basis: Supported by analytical and clinical data, including pharmacokinetic/pharmacodynamic bioequivalence and adhesive performance data.
Guidance, Outlook, and Risks
Commercial Outlook: Commercial availability of UDENYCA ONBODY is planned for the first quarter of 2024.
Risks and Uncertainties: The filing includes forward-looking statements subject to substantial risks, including:
- Risks related to existing and potential collaboration partners.
- Uncertainties inherent in the clinical drug development process.
- Competition and FDA review issues.
- Supply, manufacturing, and distribution risks for UDENYCA ONBODY.
- Potential litigation.
The Company undertakes no obligation to update forward-looking statements.
Investor Verification Checklist
- Confirm the actual commercial launch date of UDENYCA ONBODY in Q1 2024.
- Review the Company's Form 10-Q for the quarter ended September 30, 2023, for detailed risk factors.
- Monitor supply chain and manufacturing capabilities for the new on-body injector device.
- Assess market adoption rates and competitive positioning against other pegfilgrastim biosimilars.